Big pharma can only see the benefit of R&D for wealthy markets - There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries

Big pharma can only see the benefit of R&D for wealthy markets - There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries: http://bit.ly/2Wjxrzz Read more... http://bit.ly/2VDb9fd